Credit Suisse’s Design Therapeutics DSGN Stock Holding History

Credit Suisse’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1	Closed	-$10	–	3386
2022 Q4	$10	Sell	1 -191	-99%	-$2.59K	﹤0.01%	3735
2022 Q3	$3K	Buy	192 +161	+519%	+$3.2K	﹤0.01%	3669
2022 Q2	$0	Buy	+31	New	+$419	﹤0.01%	4012
2021 Q4	–	Sell	-235,938	Closed	-$3.47M	–	4535
2021 Q3	$3.47M	Sell	235,938 -4,220	-2%	-$70.2K	﹤0.01%	2359
2021 Q2	$4.78M	Buy	240,158 +178,730	+291%	+$4.51M	﹤0.01%	2114
2021 Q1	$1.84M	Buy	+61,428	New	+$2.07M	﹤0.01%	2891

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Credit Suisse's DSGN Position: Q1 2023 in Review

Credit Suisse sold out of Design Therapeutics (DSGN) in Q1 2023, closing a stake of 1 share — an estimated $10 sold.

Credit Suisse first reported a position in DSGN in Q1 2021 and held it in 6 quarters. The position peaked at $4.78M in Q2 2021. 96 funds tracked by Wall St. Rank hold DSGN as of Q1 2023.

Credit Suisse reported no remaining Design Therapeutics position as of Q1 2023 after selling out during the quarter.
Credit Suisse sold 1 Design Therapeutics share in Q1 2023, an estimated $10.
Credit Suisse first reported a position in Design Therapeutics in Q1 2021 and held it in 6 quarters.
Credit Suisse's Design Therapeutics position peaked at $4.78M in Q2 2021.
96 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.